- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S4578
| Related Targets | Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism |
|---|---|
| Other LPL Receptor Products | PF-543 AM095 TY-52156 Sonepcizumab (Anti-Sphingosine-1-phosphate) |
|
In vitro |
DMSO
: 100 mg/mL
Water : 100 mg/mL Ethanol : 100 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | Formula | (C14H22O.C2H4O.CH2O)x |
Storage (From the date of receipt) | 2 years -20°C liquid | |
|---|---|---|---|---|---|
| CAS No. | 25301-02-4 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | Triton WR1339 | Smiles | CC(C)(C)CC(C)(C)C1=CC=C(C=C1)O.C=O.C1CO1 | ||
| Targets/IC50/Ki |
lipoprotein lipase
|
|---|---|
| In vitro |
Tyloxapol is generally regarded as a safe stabilizer. In some studies, it is reported to causes cytotoxicity in epithelial and red blood cells, induces lysis of human Jurkat T-lymphoblasts and the apoptosis in RAW 264.7 murine macrophage-like cells and NIH/3T3 mouse fibroblast cells. These indications of cytotoxicity, however, do not reflect the in vivo use of this compound, since it is rarely used alone in clinical applications.
|
| In vivo |
A single intravenous injection of tyloxapol at dose of 400mg/kg body weight shows three distinctive phases, sharp linear increment, slow linear increment and slow decrement of plasma lipids toward the basal levels. The treatment of this compound enhannces the pulmonary absorption of rh-insulin and increases the absorption of inhaled insulin in diabetic rats. It might significantly increase the hypoglycemic effect of intratracheally administered insulin in diabetic rats but does not change the LDH activity.
|
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.